Glenmark Pharmaceuticals Ltd. (Glenmark), is a research-led, global pharmaceutical company, has received final approval by the United States Food & Drug Administration (FDA) for apremilast tablets, 10 mg, 20 mg and 30 mg, the generic version of Otezla tablets, 10 mg, 20 mg and 30 mg, of Amgen Inc.
Glenmark’s current portfolio consists of 188 products authorized for distribution in the US marketplace and 50 ANDA’s pending approval with the US FDA. In addition to these internal filings,
Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.
Glenmark Pharmaceuticals Limited is a research-led, global pharmaceutical company, having a presence across branded, generics, and OTC segments; with a focus on therapeutic areas of respiratory, dermatology and oncology. The company has 10 world-class manufacturing facilities spread across 4 continents, and operations in over 80 countries.
